Concord Biotech Limited vs Anthem Biosciences Limited
Last updated: 23 October 2026
Concord Biotech vs. Anthem Biosciences: A MoneyDock Comparison
In the dynamic landscape of the Indian pharmaceutical and biotechnology sector, two companies, Concord Biotech Limited and Anthem Biosciences Limited, often come under the scanner of investors. Both operate in the broader life sciences domain, albeit with different specializations. Concord Biotech is a leading developer and manufacturer of fermentation-based biopharmaceutical APIs, focusing on immunosuppressants and oncology. Anthem Biosciences, on the other hand, is a research-driven company offering contract research and manufacturing services (CRAMS) in various areas including small molecules, biologics, and peptides. This comparison aims to provide a data-driven overview of their recent market performance and key financial metrics to help investors make informed decisions, utilizing the latest available figures.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Anthem Biosciences Limited |
|---|---|---|
| Current Price | ₹1270.70 | ₹800.75 |
| 52-Week High | ₹1579.40 | ₹957.80 |
| 52-Week Low | ₹1014.80 | ₹587.85 |
| 1-Year Return | -7.88% | 18.85% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Who Wins Where?
Valuation: With both companies having 'N/A' for Trailing P/E and Market Cap, a direct valuation comparison based on these specific metrics is not possible with the provided data. However, we can observe their current price relative to their 52-week ranges. Concord Biotech is trading at ₹1270.70, which is closer to its 52-week low of ₹1014.80 than its high of ₹1579.40. Anthem Biosciences, at ₹800.75, also sits closer to its 52-week low of ₹587.85 than its high of ₹957.80. Without comprehensive valuation metrics, it's hard to declare a clear winner, but Concord Biotech has a significantly higher absolute share price.
Returns: Anthem Biosciences clearly outperforms Concord Biotech in terms of 1-year returns. Anthem Biosciences has delivered a robust 18.85% return over the past year, indicating strong positive momentum and investor confidence in its recent performance. In contrast, Concord Biotech has posted a negative return of -7.88% over the same period, suggesting a period of underperformance or correction. For investors prioritizing recent capital appreciation, Anthem Biosciences appears to be the stronger contender.
Stability: Stability can be assessed by examining the trading range relative to the current price. Concord Biotech's current price of ₹1270.70 is about 25.4% off its 52-week high and 25.2% above its 52-week low. Anthem Biosciences, at ₹800.75, is approximately 16.39% off its 52-week high and 36.21% above its 52-week low. While both are off their highs, Anthem Biosciences is further away from its 52-week low on a percentage basis, which might suggest a more significant recovery or consistent upward trend from its bottom. However, Concord's wider absolute price range might imply more volatility. Given its negative 1-year return, Concord Biotech appears to have experienced more downward pressure recently, potentially indicating less short-term price stability.
MoneyDock Verdict
For Aggressive Investors: Anthem Biosciences Limited seems more appealing for aggressive investors given its strong positive 1-year return of 18.85%. This indicates recent growth momentum which could attract those seeking higher, albeit potentially riskier, returns. Its current position further from its 52-week low suggests a positive trend.
For Conservative Investors: Neither company shows clear signals for conservative investors based purely on the provided limited data. Both lack critical valuation metrics like P/E and Market Cap, making a fundamental risk assessment difficult. Concord Biotech's negative 1-year return might deter conservatives, while Anthem's strong return might hint at a higher beta, potentially unsuitable for very risk-averse portfolios. More comprehensive financial data would be needed.
For Long-Term SIP Investors: For long-term SIP investors, Anthem Biosciences, with its positive 1-year return, might offer a more encouraging starting point. A consistent positive return trend, even over a single year, suggests better underlying performance. However, without P/E and Market Cap, assessing intrinsic value for a long-term hold remains challenging. Investors should look for deeper fundamental analysis, including earnings growth, competitive landscape, and future outlook for both companies.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.